Lv1
30 积分 2025-12-24 加入
ALK-rearranged papillary thyroid carcinoma with a germline MEN1 mutation
1个月前
已完结
Imaging Response to Ensartinib in Concurrent Papillary and Anaplastic Thyroid Carcinoma With ALK Rearrangement
2个月前
已关闭
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
6个月前
已完结
Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC
6个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: Updated analysis of data from the phase 3, randomised, open-label CROWN study
6个月前
已完结
皖公网安备34019202002308
